Changes in anti-SARS-CoV-2 antibody levels in response to COVID-19 vaccinatio
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0007311
- Lead Sponsor
- Keimyung University Dongsan Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
1. Patients who will receive or have received a SARS-CoV-2 booster vaccine among IBD patients aged 20 to 80 years
2. Crohn's disease or ulcerative colitis patients who taking at least one of agents among 5-aminosalycylic acid (ASA), immunomodulatory agents, and biological agents (infliximab, vedolizumab, ustekinumab etc)
3. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research
1. Those who have passed the booster vaccination more than 12 months ago
2. Those who have been diagnosed with IBD and have used IBD medications for less 3 months
3. Those who have had surgery within 3 months at the time of registration
4. Those who do not agree to participate in the research
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody to SARS-CoV-2
- Secondary Outcome Measures
Name Time Method Vaccine related adverse events